Outpatient physical therapy provider U.S. Physical Therapy (NYSE: USPH) reported Q3 2026 results topping the market’s revenue expectations, with sales up 11.9% year on year to $220.6 million. Its non-GAAP profit of $0.80 per share was 10.3% above analysts’ consensus estimates.

Is now the time to buy USPH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

U.S. Physical Therapy delivered a quarter that surpassed Wall Street’s expectations, with management attributing the outperformance to strong execution of its hospital partnership strategy and sustained volume growth. CEO Chris Reading credited the company’s ability to maintain record patient visits per clinic, even through a seasonally softer period, as a key factor. The integration of Metro N.Y. and Gulf Coast hospital affiliations led to a significant increase in hospital-based revenue, which in turn drove a record net rate per visit. Management also pointed to improved productivity at mature clinics and notable gains in its industrial injury prevention business, while acknowledging elevated self-insured health costs as a margin headwind.

Looking ahead, management’s guidance for the remainder of the year focuses on expanding hospital affiliations, further centralizing billing operations, and ongoing cost containment efforts. CEO Chris Reading emphasized that the company expects continued benefits from the phase-out of the Indirect Practice Cost Index (IPCI) modifier, describing it as a “very significant benefit” for efficient providers like U.S. Physical Therapy. CFO Nchacha Etta highlighted the company’s disciplined approach to labor and discretionary spending, noting, “Expense controls and margin improvements will remain key priorities as we navigate ongoing healthcare cost pressures.” Expansion of the hospital partnership model and execution on efficiency initiatives are expected to remain central to the company’s growth strategy.

Key insights from management’s remarks

Management attributed the quarter’s outperformance to hospital partnership integration, robust volume growth, and ongoing operational improvements, while expense headwinds from healthcare benefits tempered margin expansion.

• Hospital partnerships ramped up: The onboarding of Metro N.Y. and Gulf Coast hospital affiliations increased the proportion of hospital-driven revenue, which now exceeds 13% of total sales, up from less than 5% in the prior quarter. These partnerships contributed to a record net rate per visit and are expected to continue driving revenue per visit higher as more clinics are converted.

• Record patient volumes maintained: Despite seasonal headwinds, average daily visits per clinic reached new highs, marking the 27th consecutive month of record patient volumes. Management cited strong demand and effective staffing as enablers, noting ongoing competition for clinical talent in a tight labor market.

• Industrial injury prevention growth: The injury prevention segment saw double-digit revenue and profitability gains, reflecting both organic growth and the impact of earlier acquisitions. Management highlighted recurring contract wins and service expansion in manufacturing and logistics sectors.

• Self-insured health costs pressured margins: Elevated employee healthcare claims, including several large and complex cases, drove self-insured costs $2 million above budget in the quarter, reducing overall margin expansion despite underlying business improvements.

• Targeted cost controls enacted: To mitigate rising benefit costs, management implemented surgical labor reductions and discretionary spending cuts. These measures, along with revenue cycle optimization and technology investments, are expected to yield further margin benefits in future quarters.

Drivers of future performance

U.S. Physical Therapy’s outlook is shaped by ongoing hospital partnership expansion, disciplined cost management, and anticipated regulatory tailwinds.

• Expansion of hospital affiliations: Management expects additional hospital partnership conversions and de novo clinic openings to be the primary drivers of revenue growth, with both existing and new affiliations ramping up in the next few quarters. The company’s development team is focused on both organic growth and targeted acquisitions to bring additional clinics into the hospital model, which typically commands higher reimbursement rates.

• Expense management and efficiency gains: To counter persistent healthcare benefit cost inflation, management is prioritizing further labor optimization, centralization of billing and collections, and the rollout of technology solutions such as WelcomeWare in hundreds of clinics. These initiatives are designed to improve operating leverage and protect margins despite external cost pressures.

• Regulatory reimbursement changes: The anticipated phase-out of the Indirect Practice Cost Index (IPCI) modifier beginning in 2027 is expected to provide a multi-year tailwind, especially for efficient outpatient providers. Management expressed optimism that this regulatory change will enhance reimbursement rates and support sustained margin improvement.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will closely monitor (1) the pace of hospital clinic conversions and affiliated revenue growth, (2) sustained progress on labor and discretionary expense reductions to offset healthcare cost inflation, and (3) early impacts from regulatory changes such as the IPCI modifier phase-out. Execution on centralized billing initiatives and new clinic acquisitions will also serve as key indicators of management’s ability to deliver margin improvements.

U.S. Physical Therapy currently trades at $98.69, up from $89.52 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.